secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-07-23T23:54:03+00:00
Accession:  0001104659-26-086406
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics grants stock options and FDA-contingent cash bonuses to CEO and CFO
--------------------------------------------------------------------------------

- CEO Robert C. Jahr granted 100,000 stock options at $1.4304/share, vesting July 21, 2027.
- CFO Lawrence A. Kenyon granted 210,078 stock options at same price and vesting schedule.
- Cash bonuses of $420,000 (Jahr) and $200,000 (Kenyon) contingent on FDA approval of ONS-5010 by July 31, 2026.
- Bonuses awarded for 2025 service contributions and BLA advancement; no 2025 annual bonuses paid.
- Options and bonuses approved by Compensation Committee on July 21, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926086406/0001104659-26-086406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926086406/tm2621232d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-086406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer